The Debut of Inflammatory Musculoskeletal Pathology in Patients Receiving Anticancer Therapy with PD-1/PD-L1 Pathway Inhibitors

The Debut of Inflammatory Musculoskeletal Pathology in Patients Receiving Anticancer Therapy with PD-1/PD-L1 Pathway Inhibitors

Objective: to describe musculoskeletal immune-mediated adverse events (iAEs) associated with the therapy of solid tumors with immune checkpoint inhibitors (ICIs, inhibitors of the PD-1/PD-L1 pathway).Patients and methods. 13 patients receiving ICIs therapy with musculoskeletal iAEs were examined. Th...

Full description

Bibliographic Details
Main Authors: A. D. Koltakova, A. M. Lila, O. G. Alekseeva, A. A. Fedenko, Y. V. Gridneva, A. S. Olshanskaya
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2022-10-01
Series:Современная ревматология
Subjects:
immune checkpoint inhibitors
immune-mediated adverse events
immunotherapy
oncology
rheumatic complications
musculoskeletal pathology
Online Access:https://mrj.ima-press.net/mrj/article/view/1347

Similar Items

Similar Items